PMC:7205724 / 20480-23259 25 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T22399 | 0-1 | CD | denotes | 6 |
| T82716 | 3-14 | NN | denotes | Development |
| T5151 | 15-17 | IN | denotes | of |
| T20950 | 18-19 | DT | denotes | a |
| T64967 | 20-25 | JJ | denotes | human |
| T94716 | 26-36 | JJ | denotes | monoclonal |
| T29466 | 37-45 | NN | denotes | antibody |
| T27300 | 46-47 | -LRB- | denotes | ( |
| T65405 | 47-50 | NN | denotes | mAb |
| T53967 | 50-51 | -RRB- | denotes | ) |
| T20998 | 53-56 | CD | denotes | 6.1 |
| T79456 | 58-67 | VBG | denotes | Targeting |
| T24060 | 68-71 | DT | denotes | the |
| T56819 | 72-73 | NN | denotes | S |
| T25577 | 74-81 | NN | denotes | protein |
| T96682 | 83-88 | CD | denotes | 6.1.1 |
| T17328 | 90-100 | NN | denotes | Hypothesis |
| T61727 | 100-101 | -COLON- | denotes | : |
| T32221 | 102-103 | DT | denotes | A |
| T25878 | 104-107 | NN | denotes | mAb |
| T8625 | 108-115 | IN | denotes | against |
| T32030 | 116-119 | DT | denotes | the |
| T55531 | 120-127 | NN | denotes | binding |
| T9970 | 128-134 | NN | denotes | domain |
| T76093 | 135-137 | IN | denotes | of |
| T80345 | 138-141 | DT | denotes | the |
| T93532 | 142-147 | NN | denotes | virus |
| T16199 | 148-151 | MD | denotes | can |
| T28417 | 152-159 | VB | denotes | inhibit |
| T48409 | 160-169 | NN | denotes | SARS-CoV2 |
| T36310 | 170-179 | NN | denotes | infection |
| T27915 | 180-188 | RB | denotes | Recently |
| T56144 | 188-189 | -COMMA- | denotes | , |
| T55915 | 190-199 | NN | denotes | hybridoma |
| T72012 | 200-212 | NNS | denotes | supernatants |
| T47163 | 213-223 | VBG | denotes | containing |
| T24138 | 224-232 | NN | denotes | antibody |
| T98139 | 233-244 | NNS | denotes | repertoires |
| T66535 | 245-249 | IN | denotes | from |
| T86473 | 250-259 | VBN | denotes | immunized |
| T66245 | 260-270 | JJ | denotes | transgenic |
| T17100 | 271-275 | NNS | denotes | mice |
| T85324 | 276-280 | WDT | denotes | that |
| T55347 | 281-288 | VBP | denotes | express |
| T14738 | 289-292 | DT | denotes | the |
| T52540 | 293-298 | JJ | denotes | human |
| T35586 | 299-313 | NN | denotes | immunoglobulin |
| T72563 | 314-319 | JJ | denotes | heavy |
| T65069 | 320-323 | CC | denotes | and |
| T5967 | 324-329 | JJ | denotes | light |
| T98095 | 330-336 | NNS | denotes | chains |
| T78221 | 337-340 | CC | denotes | and |
| T28318 | 341-344 | NN | denotes | rat |
| T19776 | 345-351 | NN | denotes | origin |
| T32531 | 352-366 | NN | denotes | immunoglobulin |
| T16968 | 367-375 | NN | denotes | constant |
| T56920 | 376-383 | NNS | denotes | regions |
| T36716 | 384-388 | VBD | denotes | were |
| T74827 | 389-393 | VBN | denotes | used |
| T21382 | 394-396 | TO | denotes | to |
| T11788 | 397-403 | VB | denotes | detect |
| T40665 | 404-414 | NNS | denotes | antibodies |
| T56747 | 415-419 | WDT | denotes | that |
| T54239 | 420-423 | MD | denotes | can |
| T71867 | 424-429 | VB | denotes | cross |
| T35671 | 430-440 | VB | denotes | neutralize |
| T77445 | 441-447 | NN | denotes | SARS-S |
| T34654 | 448-451 | CC | denotes | and |
| T83470 | 452-460 | NN | denotes | SARS-2-S |
| T76245 | 461-462 | -LRB- | denotes | [ |
| T33581 | 462-464 | CD | denotes | 26 |
| T80577 | 464-465 | -RRB- | denotes | ] |
| T78516 | 467-470 | CD | denotes | One |
| T34464 | 471-479 | JJ | denotes | chimeric |
| T13041 | 480-485 | NN | denotes | 47D11 |
| T83927 | 486-490 | NN | denotes | H2L2 |
| T57345 | 491-499 | NN | denotes | antibody |
| T44833 | 500-509 | VBD | denotes | displayed |
| T94688 | 510-514 | PDT | denotes | such |
| T52983 | 515-516 | DT | denotes | a |
| T30646 | 517-535 | JJ | denotes | cross-neutralizing |
| T37245 | 536-544 | NN | denotes | activity |
| T11300 | 544-545 | -COMMA- | denotes | , |
| T30814 | 546-555 | VBD | denotes | decreased |
| T23282 | 556-564 | NN | denotes | syncytia |
| T72581 | 565-574 | NN | denotes | formation |
| T71888 | 575-582 | VBN | denotes | induced |
| T44111 | 583-585 | IN | denotes | by |
| T7869 | 586-592 | NN | denotes | SARS-S |
| T80909 | 593-596 | CC | denotes | and |
| T58127 | 597-604 | NN | denotes | SARS2-S |
| T9479 | 604-605 | -COMMA- | denotes | , |
| T96346 | 606-609 | CC | denotes | and |
| T43362 | 610-615 | MD | denotes | could |
| T48435 | 616-623 | VB | denotes | protect |
| T44775 | 624-630 | NN | denotes | VeroE6 |
| T25625 | 631-636 | NNS | denotes | cells |
| T19104 | 637-644 | IN | denotes | against |
| T51640 | 645-651 | NN | denotes | SARS-S |
| T22676 | 652-655 | CC | denotes | and |
| T37470 | 656-663 | NN | denotes | SARS2-S |
| T64695 | 664-675 | VBD | denotes | pseudotyped |
| T26978 | 676-681 | NN | denotes | virus |
| T79137 | 682-683 | -LRB- | denotes | [ |
| T95558 | 683-685 | CD | denotes | 26 |
| T95168 | 685-686 | -RRB- | denotes | ] |
| T45371 | 688-690 | PRP | denotes | It |
| T75403 | 691-694 | MD | denotes | may |
| T86603 | 695-698 | VB | denotes | lie |
| T91829 | 699-701 | IN | denotes | in |
| T48175 | 702-705 | PRP-DOLLAR- | denotes | its |
| T69338 | 706-713 | JJ | denotes | similar |
| T68140 | 714-724 | NNS | denotes | affinities |
| T76951 | 725-728 | IN | denotes | for |
| T38362 | 729-740 | VBG | denotes | interacting |
| T39715 | 741-745 | IN | denotes | with |
| T48378 | 746-749 | DT | denotes | the |
| T63623 | 750-754 | JJ | denotes | same |
| T2491 | 755-761 | NN | denotes | domain |
| T57621 | 762-764 | IN | denotes | of |
| T77993 | 765-768 | DT | denotes | the |
| T52886 | 769-771 | NN | denotes | S1 |
| T27554 | 772-779 | NN | denotes | subunit |
| T41139 | 779-780 | -COMMA- | denotes | , |
| T99819 | 781-785 | FW | denotes | i.e. |
| T40027 | 785-786 | -COMMA- | denotes | , |
| T73637 | 787-790 | NN | denotes | S1B |
| T71055 | 790-791 | -COMMA- | denotes | , |
| T88888 | 792-794 | IN | denotes | of |
| T40209 | 795-799 | DT | denotes | each |
| T2572 | 800-806 | NN | denotes | SARS-S |
| T97128 | 807-810 | CC | denotes | and |
| T91104 | 811-819 | NN | denotes | SARS-2-S |
| T63608 | 822-827 | CD | denotes | 6.1.2 |
| T11815 | 829-837 | NNP | denotes | Rational |
| T73902 | 837-838 | -COLON- | denotes | : |
| T21134 | 839-842 | DT | denotes | The |
| T30867 | 843-851 | JJ | denotes | chimeric |
| T42126 | 852-857 | NN | denotes | 47D11 |
| T93924 | 858-862 | NN | denotes | H2L2 |
| T85248 | 863-868 | MD | denotes | might |
| T92338 | 869-872 | RB | denotes | not |
| T49873 | 873-875 | VB | denotes | be |
| T69919 | 876-885 | JJ | denotes | effective |
| T60557 | 886-888 | IN | denotes | in |
| T77242 | 889-894 | JJ | denotes | human |
| T86725 | 895-899 | NN | denotes | lung |
| T18333 | 900-905 | NNS | denotes | cells |
| T22947 | 906-908 | IN | denotes | as |
| T22184 | 909-911 | PRP | denotes | it |
| T1922 | 912-914 | VBZ | denotes | is |
| T72123 | 915-917 | FW | denotes | in |
| T38972 | 918-923 | FW | denotes | vitro |
| T22398 | 924-929 | NN | denotes | 47D11 |
| T15962 | 930-937 | VBD | denotes | carried |
| T83196 | 938-939 | DT | denotes | a |
| T61532 | 940-946 | JJR | denotes | higher |
| T47874 | 947-955 | NN | denotes | affinity |
| T77580 | 956-959 | IN | denotes | for |
| T95631 | 960-971 | VBG | denotes | interacting |
| T94847 | 972-976 | IN | denotes | with |
| T20163 | 977-980 | DT | denotes | the |
| T18520 | 981-983 | NN | denotes | S2 |
| T89003 | 984-991 | NN | denotes | subunit |
| T41606 | 992-994 | IN | denotes | of |
| T4784 | 995-1001 | NN | denotes | SARS-S |
| T32288 | 1002-1006 | IN | denotes | than |
| T68894 | 1007-1011 | DT | denotes | that |
| T97000 | 1012-1014 | IN | denotes | of |
| T32517 | 1015-1024 | NN | denotes | SARS-2-S. |
| T24633 | 1025-1027 | PRP | denotes | It |
| T45480 | 1028-1030 | VBZ | denotes | is |
| T10954 | 1031-1040 | JJ | denotes | important |
| T96386 | 1041-1045 | IN | denotes | that |
| T80967 | 1046-1049 | IN | denotes | for |
| T24571 | 1050-1054 | DT | denotes | both |
| T18211 | 1055-1061 | NN | denotes | SARS-S |
| T39196 | 1062-1065 | CC | denotes | and |
| T83081 | 1066-1074 | NN | denotes | SARS-2-S |
| T70298 | 1074-1075 | -COMMA- | denotes | , |
| T91479 | 1076-1079 | DT | denotes | the |
| T56884 | 1080-1087 | NN | denotes | binding |
| T11559 | 1088-1090 | IN | denotes | of |
| T2922 | 1091-1094 | DT | denotes | the |
| T11592 | 1095-1100 | NN | denotes | 47D11 |
| T36887 | 1101-1109 | NN | denotes | antibody |
| T46706 | 1110-1112 | TO | denotes | to |
| T40788 | 1113-1116 | DT | denotes | the |
| T37833 | 1117-1123 | NN | denotes | target |
| T37378 | 1124-1125 | VBZ | denotes | – |
| T15003 | 1126-1129 | DT | denotes | the |
| T4372 | 1130-1133 | NN | denotes | S1B |
| T31100 | 1134-1140 | NN | denotes | domain |
| T82065 | 1141-1142 | NN | denotes | – |
| T43926 | 1143-1147 | VBZ | denotes | does |
| T69422 | 1148-1151 | RB | denotes | not |
| T3419 | 1152-1157 | VB | denotes | block |
| T21955 | 1158-1161 | DT | denotes | the |
| T12942 | 1162-1169 | NN | denotes | binding |
| T83444 | 1170-1172 | IN | denotes | of |
| T49120 | 1173-1176 | NN | denotes | S1B |
| T55070 | 1177-1180 | CC | denotes | and |
| T98634 | 1181-1183 | NN | denotes | S2 |
| T48321 | 1184-1186 | TO | denotes | to |
| T80580 | 1187-1191 | NN | denotes | ACE2 |
| T18877 | 1192-1200 | NN | denotes | receptor |
| T18503 | 1201-1202 | -LRB- | denotes | [ |
| T33177 | 1202-1204 | CD | denotes | 26 |
| T92006 | 1204-1205 | -RRB- | denotes | ] |
| T53652 | 1207-1209 | IN | denotes | By |
| T58622 | 1210-1218 | NN | denotes | contrast |
| T35381 | 1218-1219 | -COMMA- | denotes | , |
| T41843 | 1220-1232 | VBG | denotes | neutralizing |
| T81589 | 1233-1243 | NNS | denotes | antibodies |
| T68196 | 1244-1248 | WDT | denotes | that |
| T30816 | 1249-1261 | RB | denotes | specifically |
| T53446 | 1262-1268 | NN | denotes | target |
| T89813 | 1269-1275 | NN | denotes | SARS-S |
| T95236 | 1276-1281 | MD | denotes | could |
| T7888 | 1282-1289 | VB | denotes | compete |
| T34125 | 1290-1294 | IN | denotes | with |
| T82101 | 1295-1298 | NN | denotes | S1B |
| T1902 | 1299-1302 | CC | denotes | and |
| T24277 | 1303-1305 | NN | denotes | S2 |
| T37015 | 1306-1309 | IN | denotes | for |
| T86465 | 1310-1317 | VBG | denotes | binding |
| T1893 | 1318-1320 | TO | denotes | to |
| T91196 | 1321-1325 | NN | denotes | ACE2 |
| T54390 | 1328-1331 | CD | denotes | 6.2 |
| T7377 | 1333-1342 | VBG | denotes | Targeting |
| T2754 | 1343-1359 | JJ | denotes | pro-inflammatory |
| T79617 | 1360-1369 | NNS | denotes | cytokines |
| T42975 | 1371-1376 | CD | denotes | 6.2.1 |
| T96891 | 1378-1388 | NN | denotes | Hypothesis |
| T41163 | 1388-1389 | -COLON- | denotes | : |
| T35174 | 1390-1391 | DT | denotes | A |
| T74401 | 1392-1395 | NN | denotes | mAb |
| T75556 | 1396-1403 | IN | denotes | against |
| T83617 | 1404-1407 | NN | denotes | IL6 |
| T67953 | 1408-1411 | MD | denotes | can |
| T68840 | 1412-1421 | VB | denotes | attenuate |
| T2426 | 1422-1427 | NN | denotes | hyper |
| T92661 | 1428-1440 | NN | denotes | inflammation |
| T86439 | 1441-1452 | NNP | denotes | Tocilizumab |
| T21494 | 1452-1453 | -COMMA- | denotes | , |
| T50157 | 1454-1458 | RB | denotes | also |
| T26283 | 1459-1464 | VBN | denotes | known |
| T43571 | 1465-1467 | IN | denotes | as |
| T44785 | 1468-1477 | NN | denotes | atlizumab |
| T96810 | 1477-1478 | -COMMA- | denotes | , |
| T58761 | 1479-1481 | VBZ | denotes | is |
| T56416 | 1482-1483 | DT | denotes | a |
| T79548 | 1484-1493 | JJ | denotes | humanized |
| T29074 | 1494-1504 | JJ | denotes | anti-human |
| T88685 | 1505-1508 | NN | denotes | IL6 |
| T26777 | 1509-1517 | NN | denotes | receptor |
| T24185 | 1518-1526 | NN | denotes | antibody |
| T17221 | 1527-1535 | VBN | denotes | approved |
| T32471 | 1536-1538 | IN | denotes | by |
| T53882 | 1539-1542 | NNP | denotes | FDA |
| T24580 | 1543-1546 | IN | denotes | for |
| T33924 | 1547-1554 | JJ | denotes | several |
| T90119 | 1555-1567 | JJ | denotes | inflammatory |
| T59846 | 1568-1571 | CC | denotes | and |
| T31666 | 1572-1582 | JJ | denotes | autoimmune |
| T46803 | 1583-1591 | NNS | denotes | diseases |
| T80969 | 1592-1598 | JJ | denotes | severe |
| T13017 | 1598-1599 | -COMMA- | denotes | , |
| T79015 | 1600-1604 | JJ | denotes | such |
| T43255 | 1605-1607 | IN | denotes | as |
| T47553 | 1608-1616 | NN | denotes | cytokine |
| T34694 | 1617-1624 | NN | denotes | release |
| T36705 | 1625-1633 | NN | denotes | syndrome |
| T68837 | 1633-1634 | -COMMA- | denotes | , |
| T30269 | 1635-1645 | JJ | denotes | rheumatoid |
| T54700 | 1646-1655 | NN | denotes | arthritis |
| T81658 | 1655-1656 | -COMMA- | denotes | , |
| T84650 | 1657-1662 | JJ | denotes | giant |
| T11095 | 1663-1667 | NN | denotes | cell |
| T15987 | 1668-1677 | NN | denotes | arteritis |
| T88887 | 1677-1678 | -COMMA- | denotes | , |
| T31599 | 1679-1692 | JJ | denotes | polyarticular |
| T93322 | 1693-1701 | JJ | denotes | juvenile |
| T49595 | 1702-1712 | JJ | denotes | idiopathic |
| T62141 | 1713-1722 | NN | denotes | arthritis |
| T76737 | 1722-1723 | -COMMA- | denotes | , |
| T30470 | 1724-1727 | CC | denotes | and |
| T13999 | 1728-1738 | JJ | denotes | systematic |
| T88238 | 1739-1747 | JJ | denotes | juvenile |
| T89892 | 1748-1758 | JJ | denotes | idiopathic |
| T97598 | 1759-1768 | NN | denotes | arthritis |
| T25454 | 1770-1772 | PRP | denotes | It |
| T28665 | 1773-1775 | VBZ | denotes | is |
| T15312 | 1776-1780 | JJ | denotes | safe |
| T18121 | 1781-1784 | CC | denotes | and |
| T2467 | 1785-1794 | JJ | denotes | effective |
| T39207 | 1795-1798 | IN | denotes | for |
| T89869 | 1799-1803 | DT | denotes | both |
| T32842 | 1804-1810 | NNS | denotes | adults |
| T38357 | 1811-1814 | CC | denotes | and |
| T13891 | 1815-1823 | NNS | denotes | children |
| T61388 | 1824-1827 | CD | denotes | two |
| T66576 | 1828-1833 | NNS | denotes | years |
| T46590 | 1834-1836 | IN | denotes | of |
| T15404 | 1837-1840 | NN | denotes | age |
| T19164 | 1841-1844 | CC | denotes | and |
| T99851 | 1845-1850 | JJR | denotes | older |
| T41884 | 1853-1858 | CD | denotes | 6.2.2 |
| T3706 | 1860-1869 | NNP | denotes | Rationale |
| T87509 | 1869-1870 | -COLON- | denotes | : |
| T72411 | 1871-1882 | NNP | denotes | Tocilizumab |
| T46139 | 1883-1886 | MD | denotes | can |
| T80638 | 1887-1892 | VB | denotes | treat |
| T14365 | 1893-1897 | NN | denotes | lung |
| T88114 | 1898-1904 | NN | denotes | injury |
| T76208 | 1905-1907 | IN | denotes | in |
| T24628 | 1908-1916 | NNS | denotes | patients |
| T15777 | 1917-1921 | IN | denotes | with |
| T58130 | 1922-1930 | JJ | denotes | critical |
| T31522 | 1931-1934 | CC | denotes | and |
| T55163 | 1935-1941 | JJ | denotes | severe |
| T92225 | 1942-1950 | NN | denotes | COVID-19 |
| T21073 | 1951-1953 | IN | denotes | In |
| T65150 | 1954-1957 | DT | denotes | the |
| T61991 | 1958-1963 | NN | denotes | study |
| T18474 | 1964-1965 | -LRB- | denotes | [ |
| T8341 | 1965-1967 | CD | denotes | 27 |
| T6430 | 1967-1968 | -RRB- | denotes | ] |
| T29393 | 1968-1969 | -COMMA- | denotes | , |
| T77821 | 1970-1972 | CD | denotes | 21 |
| T79215 | 1973-1981 | NNS | denotes | patients |
| T5404 | 1982-1986 | IN | denotes | with |
| T75582 | 1987-1995 | NN | denotes | COVID-19 |
| T89299 | 1996-2001 | WP-DOLLAR- | denotes | whose |
| T66055 | 2002-2011 | NN | denotes | condition |
| T80340 | 2012-2015 | VBD | denotes | was |
| T3490 | 2016-2022 | JJ | denotes | severe |
| T44653 | 2023-2025 | CC | denotes | or |
| T55941 | 2026-2034 | JJ | denotes | critical |
| T85453 | 2035-2043 | VBD | denotes | received |
| T98598 | 2044-2047 | CD | denotes | one |
| T96881 | 2048-2050 | CC | denotes | or |
| T24534 | 2051-2054 | CD | denotes | two |
| T70238 | 2055-2060 | NNS | denotes | doses |
| T20616 | 2061-2063 | IN | denotes | of |
| T68912 | 2064-2075 | NNP | denotes | Tocilizumab |
| T98192 | 2076-2080 | CC | denotes | plus |
| T20706 | 2081-2089 | JJ | denotes | standard |
| T58005 | 2090-2097 | NN | denotes | therapy |
| T96625 | 2099-2107 | NNS | denotes | Patients |
| T75572 | 2108-2111 | WP | denotes | who |
| T31917 | 2112-2115 | VBD | denotes | had |
| T15301 | 2116-2117 | DT | denotes | a |
| T24848 | 2118-2122 | JJ | denotes | mean |
| T84688 | 2123-2126 | NN | denotes | IL6 |
| T96963 | 2127-2132 | NN | denotes | level |
| T6930 | 2133-2135 | IN | denotes | of |
| T90933 | 2136-2140 | JJR | denotes | more |
| T81944 | 2141-2145 | IN | denotes | than |
| T75581 | 2146-2155 | NN | denotes | 100 pg/ml |
| T64021 | 2156-2162 | IN | denotes | before |
| T9387 | 2163-2174 | NN | denotes | tocilizumab |
| T84664 | 2175-2184 | NN | denotes | treatment |
| T18203 | 2185-2191 | VBD | denotes | showed |
| T60803 | 2192-2203 | NN | denotes | improvement |
| T44490 | 2204-2206 | IN | denotes | in |
| T81402 | 2207-2215 | JJ | denotes | clinical |
| T14228 | 2216-2224 | NNS | denotes | symptoms |
| T94537 | 2225-2228 | CC | denotes | and |
| T83697 | 2229-2239 | JJ | denotes | peripheral |
| T13978 | 2240-2246 | NN | denotes | oxygen |
| T35808 | 2247-2257 | NN | denotes | saturation |
| T34900 | 2258-2261 | CC | denotes | and |
| T75964 | 2262-2275 | NN | denotes | normalization |
| T84268 | 2276-2279 | IN | denotes | for |
| T65028 | 2280-2290 | NN | denotes | lymphocyte |
| T34390 | 2291-2301 | NN | denotes | proportion |
| T96610 | 2302-2305 | CC | denotes | and |
| T30755 | 2306-2309 | NN | denotes | CRP |
| T63070 | 2310-2316 | NNS | denotes | levels |
| T31791 | 2318-2322 | RB | denotes | Also |
| T31152 | 2322-2323 | -COMMA- | denotes | , |
| T79595 | 2324-2328 | NN | denotes | lung |
| T51431 | 2329-2335 | NN | denotes | lesion |
| T10130 | 2336-2343 | NN | denotes | opacity |
| T31388 | 2344-2347 | VBD | denotes | was |
| T1824 | 2348-2356 | VBN | denotes | absorbed |
| T60055 | 2357-2359 | IN | denotes | in |
| T38598 | 2360-2362 | CD | denotes | 90 |
| T67288 | 2362-2363 | NN | denotes | % |
| T48683 | 2364-2366 | IN | denotes | of |
| T41529 | 2367-2375 | NNS | denotes | patients |
| T69670 | 2377-2384 | CC | denotes | Neither |
| T9277 | 2385-2392 | JJ | denotes | serious |
| T15021 | 2393-2400 | JJ | denotes | adverse |
| T23626 | 2401-2408 | NNS | denotes | effects |
| T98539 | 2409-2412 | CC | denotes | nor |
| T65699 | 2413-2419 | NNS | denotes | deaths |
| T50204 | 2420-2428 | VBD | denotes | occurred |
| T20973 | 2429-2433 | IN | denotes | with |
| T14012 | 2434-2445 | NN | denotes | tocilizumab |
| T66286 | 2446-2455 | NN | denotes | treatment |
| T24269 | 2457-2462 | EX | denotes | There |
| T26765 | 2463-2466 | VBP | denotes | are |
| T84711 | 2467-2474 | VBG | denotes | ongoing |
| T74304 | 2475-2483 | JJ | denotes | clinical |
| T68003 | 2484-2490 | NNS | denotes | trials |
| T5000 | 2491-2494 | IN | denotes | for |
| T64198 | 2495-2506 | NN | denotes | tocilizumab |
| T83078 | 2507-2516 | NN | denotes | treatment |
| T11331 | 2517-2519 | IN | denotes | in |
| T42834 | 2520-2528 | NNS | denotes | patients |
| T27205 | 2529-2533 | IN | denotes | with |
| T23786 | 2534-2542 | JJ | denotes | moderate |
| T45333 | 2543-2546 | CC | denotes | and |
| T9137 | 2547-2553 | JJ | denotes | severe |
| T27842 | 2554-2562 | NN | denotes | COVID-19 |
| T92236 | 2564-2573 | RB | denotes | Currently |
| T32112 | 2573-2574 | -COMMA- | denotes | , |
| T54987 | 2575-2578 | DT | denotes | the |
| T85855 | 2579-2582 | NN | denotes | use |
| T69355 | 2583-2585 | IN | denotes | of |
| T40115 | 2586-2597 | NNP | denotes | Tocilizumab |
| T10850 | 2598-2600 | VBZ | denotes | is |
| T78367 | 2601-2612 | VBN | denotes | recommended |
| T33042 | 2613-2616 | IN | denotes | for |
| T36466 | 2617-2625 | NNS | denotes | patients |
| T61983 | 2626-2630 | IN | denotes | with |
| T2749 | 2631-2639 | NN | denotes | COVID-19 |
| T17580 | 2640-2643 | WP | denotes | who |
| T69055 | 2644-2648 | VBP | denotes | have |
| T71996 | 2649-2656 | VBG | denotes | warning |
| T59356 | 2657-2662 | NNS | denotes | signs |
| T65527 | 2663-2665 | IN | denotes | of |
| T99769 | 2666-2671 | NN | denotes | hyper |
| T44301 | 2672-2684 | NN | denotes | inflammation |
| T54453 | 2684-2685 | -COMMA- | denotes | , |
| T58078 | 2686-2688 | IN | denotes | as |
| T75237 | 2689-2692 | MD | denotes | can |
| T7496 | 2693-2695 | VB | denotes | be |
| T53845 | 2696-2704 | VBN | denotes | measured |
| T78207 | 2705-2707 | IN | denotes | by |
| T88455 | 2708-2711 | NN | denotes | IL6 |
| T77671 | 2711-2712 | -COMMA- | denotes | , |
| T67481 | 2713-2721 | NN | denotes | ferritin |
| T99390 | 2721-2722 | -COMMA- | denotes | , |
| T23484 | 2723-2731 | NN | denotes | platelet |
| T65701 | 2732-2738 | NNS | denotes | counts |
| T30323 | 2738-2739 | -COMMA- | denotes | , |
| T72053 | 2740-2752 | JJ | denotes | inflammatory |
| T81575 | 2753-2760 | NNS | denotes | markers |
| T96428 | 2760-2761 | -COMMA- | denotes | , |
| T36542 | 2762-2765 | CC | denotes | and |
| T88469 | 2766-2767 | NN | denotes | H |
| T51141 | 2768-2773 | NN | denotes | score |
| T97739 | 2774-2775 | -LRB- | denotes | [ |
| T29313 | 2775-2777 | CD | denotes | 28 |
| T54016 | 2777-2778 | -RRB- | denotes | ] |
| R10178 | T33581 | T76245 | arg2Of | 26,[ |
| R10371 | T37833 | T46706 | arg2Of | target,to |
| R10518 | T98095 | T5967 | arg1Of | chains,light |
| R10738 | T17100 | T86473 | arg2Of | mice,immunized |
| R10896 | T63070 | T65028 | arg1Of | levels,lymphocyte |
| R10947 | T68894 | T97000 | arg1Of | that,of |
| R12091 | T60803 | T44490 | arg1Of | improvement,in |
| R12170 | T62141 | T88887 | arg2Of | arthritis,"," |
| R12224 | T80577 | T76245 | arg3Of | ],[ |
| R12475 | T15987 | T11095 | arg1Of | arteritis,cell |
| R12801 | T11788 | T21382 | arg1Of | detect,to |
| R13130 | T30755 | T96610 | arg2Of | CRP,and |
| R13146 | T26283 | T50157 | arg1Of | known,also |
| R13154 | T85855 | T7496 | arg1Of | use,be |
| R13264 | T44301 | T99769 | arg1Of | inflammation,hyper |
| R13465 | T46803 | T33924 | arg1Of | diseases,several |
| R14004 | T66055 | T89299 | arg1Of | condition,whose |
| R14488 | T29466 | T5151 | arg2Of | antibody,of |
| R14765 | T96891 | T68840 | arg1Of | Hypothesis,attenuate |
| R14961 | T89813 | T53446 | arg1Of | SARS-S,target |
| R15040 | T95631 | T94847 | arg1Of | interacting,with |
| R15083 | T36542 | T96428 | arg1Of | and,"," |
| R15396 | T25878 | T28417 | arg1Of | mAb,inhibit |
| R15467 | T37378 | T70298 | arg1Of | –,"," |
| R15531 | T77671 | T99390 | arg1Of | ",","," |
| R16446 | T47874 | T45480 | modOf | affinity,is |
| R16905 | T68003 | T84711 | arg1Of | trials,ongoing |
| R17122 | T2491 | T39715 | arg2Of | domain,with |
| R17475 | T68140 | T76951 | arg1Of | affinities,for |
| R17566 | T56884 | T37378 | arg1Of | binding,– |
| R17601 | T27842 | T27205 | arg2Of | COVID-19,with |
| R18021 | T53882 | T17221 | arg1Of | FDA,approved |
| R19206 | T53845 | T78207 | arg1Of | measured,by |
| R19260 | T54700 | T68837 | arg2Of | arthritis,"," |
| R19276 | T24185 | T56416 | arg1Of | antibody,a |
| R19638 | T30470 | T76737 | arg1Of | and,"," |
| R20587 | T25878 | T16199 | arg1Of | mAb,can |
| R20598 | T55163 | T31522 | arg2Of | severe,and |
| R2062 | T97128 | T40209 | arg1Of | and,each |
| R20734 | T80969 | T24580 | arg2Of | severe,for |
| R20864 | T81658 | T88887 | arg1Of | ",","," |
| R21368 | T24628 | T15777 | arg1Of | patients,with |
| R21425 | T95168 | T79137 | arg3Of | ],[ |
| R21524 | T24185 | T26777 | arg1Of | antibody,receptor |
| R21619 | T34900 | T94537 | arg2Of | and,and |
| R21959 | T36705 | T34694 | arg1Of | syndrome,release |
| R21977 | T81575 | T30323 | arg2Of | markers,"," |
| R22045 | T86603 | T75403 | arg2Of | lie,may |
| R22400 | T44301 | T65527 | arg2Of | inflammation,of |
| R22449 | T98539 | T69670 | arg1Of | nor,Neither |
| R2263 | T24185 | T88685 | arg1Of | antibody,IL6 |
| R22781 | T18333 | T77242 | arg1Of | cells,human |
| R2282 | T67481 | T77671 | arg2Of | ferritin,"," |
| R22914 | T98139 | T55347 | arg1Of | repertoires,express |
| R23617 | T3419 | T37378 | arg2Of | block,– |
| R23833 | T9970 | T8625 | arg2Of | domain,against |
| R23852 | T97598 | T89892 | arg1Of | arthritis,idiopathic |
| R23893 | T26978 | T64695 | arg3Of | virus,pseudotyped |
| R2391 | T7888 | T30816 | arg1Of | compete,specifically |
| R24043 | T38362 | T76951 | arg2Of | interacting,for |
| R24087 | T24185 | T79548 | arg1Of | antibody,humanized |
| R24341 | T43255 | T79015 | arg1Of | as,such |
| R24714 | T40665 | T71867 | arg1Of | antibodies,cross |
| R24887 | T35808 | T13978 | arg1Of | saturation,oxygen |
| R24950 | T38357 | T99851 | arg1Of | and,older |
| R24972 | T68140 | T41139 | arg1Of | affinities,"," |
| R25119 | T28417 | T16199 | arg2Of | inhibit,can |
| R25403 | T3490 | T44653 | arg1Of | severe,or |
| R25517 | T89003 | T94847 | arg2Of | subunit,with |
| R25704 | T98139 | T47163 | arg2Of | repertoires,containing |
| R26554 | T83078 | T5000 | arg2Of | treatment,for |
| R26619 | T82065 | T15003 | arg1Of | –,the |
| R2665 | T97598 | T13999 | arg1Of | arthritis,systematic |
| R26904 | T85855 | T78367 | arg2Of | use,recommended |
| R27191 | T23626 | T98539 | arg1Of | effects,nor |
| R27208 | T45371 | T86603 | arg1Of | It,lie |
| R27252 | T93924 | T30867 | arg1Of | H2L2,chimeric |
| R27294 | T1824 | T31388 | arg2Of | absorbed,was |
| R27449 | T83078 | T64198 | arg1Of | treatment,tocilizumab |
| R27501 | T51141 | T36542 | arg2Of | score,and |
| R2759 | T62141 | T31599 | arg1Of | arthritis,polyarticular |
| R27739 | T61991 | T21073 | arg2Of | study,In |
| R27880 | T10954 | T45480 | arg2Of | important,is |
| R27887 | T17221 | T24580 | arg1Of | approved,for |
| R28465 | T23786 | T45333 | arg1Of | moderate,and |
| R28532 | T25577 | T79456 | arg2Of | protein,Targeting |
| R29264 | T44653 | T80340 | arg2Of | or,was |
| R29418 | T35671 | T71867 | arg2Of | neutralize,cross |
| R29518 | T68003 | T5000 | arg1Of | trials,for |
| R2953 | T72581 | T23282 | arg1Of | formation,syncytia |
| R29604 | T88114 | T80638 | arg2Of | injury,treat |
| R29816 | T2491 | T63623 | arg1Of | domain,same |
| R30062 | T42834 | T27205 | arg1Of | patients,with |
| R30150 | T12942 | T83444 | arg1Of | binding,of |
| R3039 | T79215 | T5404 | arg1Of | patients,with |
| R30509 | T27554 | T52886 | arg1Of | subunit,S1 |
| R30813 | T93924 | T69919 | arg1Of | H2L2,effective |
| R30853 | T86603 | T91829 | arg1Of | lie,in |
| R31375 | T75582 | T5404 | arg2Of | COVID-19,with |
| R31979 | T9970 | T76093 | arg1Of | domain,of |
| R32317 | T57345 | T30814 | arg1Of | antibody,decreased |
| R32577 | T74401 | T41163 | arg2Of | mAb,: |
| R32719 | T17328 | T96682 | arg1Of | Hypothesis,6.1.1 |
| R33248 | T30470 | T43255 | arg2Of | and,as |
| R33385 | T25454 | T15312 | arg1Of | It,safe |
| R33694 | T48435 | T43362 | arg2Of | protect,could |
| R33791 | T99851 | T19164 | arg2Of | older,and |
| R33937 | T56920 | T78221 | arg2Of | regions,and |
| R3397 | T47874 | T83196 | arg1Of | affinity,a |
| R33983 | T74827 | T27915 | arg1Of | used,Recently |
| R34037 | T68003 | T74304 | arg1Of | trials,clinical |
| R34196 | T13891 | T38357 | arg2Of | children,and |
| R34441 | T17328 | T61727 | arg1Of | Hypothesis,: |
| R34556 | T89003 | T41606 | arg1Of | subunit,of |
| R34720 | T3419 | T43926 | arg2Of | block,does |
| R34990 | T99819 | T40027 | arg1Of | i.e.,"," |
| R35135 | T36466 | T69055 | arg1Of | patients,have |
| R35148 | T12942 | T21955 | arg1Of | binding,the |
| R3528 | T98634 | T55070 | arg2Of | S2,and |
| R35318 | T2572 | T97128 | arg1Of | SARS-S,and |
| R35747 | T56884 | T46706 | arg1Of | binding,to |
| R36055 | T55070 | T83444 | arg2Of | and,of |
| R3636 | T91196 | T1893 | arg2Of | ACE2,to |
| R36916 | T37833 | T40788 | arg1Of | target,the |
| R37042 | T18877 | T80580 | arg1Of | receptor,ACE2 |
| R37082 | T57345 | T44833 | arg1Of | antibody,displayed |
| R37108 | T22398 | T15962 | arg1Of | 47D11,carried |
| R37231 | T98539 | T50204 | arg1Of | nor,occurred |
| R37253 | T11300 | T96346 | arg1Of | ",",and |
| R37476 | T40665 | T54239 | arg1Of | antibodies,can |
| R37501 | T66576 | T61388 | arg1Of | years,two |
| R37530 | T80638 | T46139 | arg2Of | treat,can |
| R37706 | T4784 | T41606 | arg2Of | SARS-S,of |
| R37793 | T96625 | T75572 | arg1Of | Patients,who |
| R3792 | T65405 | T27300 | arg2Of | mAb,( |
| R3874 | T2491 | T57621 | arg1Of | domain,of |
| R39175 | T82101 | T1902 | arg1Of | S1B,and |
| R39394 | T93924 | T21134 | arg1Of | H2L2,The |
| R39715 | T72581 | T71888 | arg2Of | formation,induced |
| R3997 | T89003 | T18520 | arg1Of | subunit,S2 |
| R40504 | T89813 | T7888 | arg1Of | SARS-S,compete |
| R40933 | T36542 | T78207 | arg2Of | and,by |
| R41077 | T92006 | T18503 | arg3Of | ],[ |
| R41615 | T51141 | T97739 | arg1Of | score,[ |
| R41949 | T36705 | T68837 | arg1Of | syndrome,"," |
| R42046 | T15987 | T84650 | arg1Of | arteritis,giant |
| R42067 | T53967 | T27300 | arg3Of | ),( |
| R42123 | T70238 | T85453 | arg2Of | doses,received |
| R42165 | T37245 | T44833 | arg2Of | activity,displayed |
| R42535 | T41843 | T35381 | arg1Of | neutralizing,"," |
| R42573 | T22676 | T64695 | arg2Of | and,pseudotyped |
| R42821 | T97598 | T88238 | arg1Of | arthritis,juvenile |
| R42879 | T98539 | T9277 | arg1Of | nor,serious |
| R43602 | T47874 | T15962 | arg2Of | affinity,carried |
| R44206 | T82716 | T22399 | arg1Of | Development,6 |
| R44270 | T97128 | T88888 | arg2Of | and,of |
| R44320 | T25625 | T48435 | arg2Of | cells,protect |
| R4444 | T31666 | T59846 | arg2Of | autoimmune,and |
| R4477 | T92225 | T55163 | arg1Of | COVID-19,severe |
| R44975 | T10130 | T1824 | arg2Of | opacity,absorbed |
| R45357 | T36705 | T47553 | arg1Of | syndrome,cytokine |
| R45591 | T37378 | T96386 | arg2Of | –,that |
| R45661 | T90933 | T64021 | arg1Of | more,before |
| R45757 | T81589 | T68196 | arg1Of | antibodies,that |
| R45826 | T47874 | T32288 | arg1Of | affinity,than |
| R46895 | T29466 | T94716 | arg1Of | antibody,monoclonal |
| R47400 | T82065 | T43926 | arg1Of | –,does |
| R47508 | T97598 | T30470 | arg2Of | arthritis,and |
| R47571 | T2491 | T48378 | arg1Of | domain,the |
| R48015 | T68140 | T99819 | arg1Of | affinities,i.e. |
| R48027 | T7888 | T34125 | arg1Of | compete,with |
| R48338 | T24185 | T58761 | arg2Of | antibody,is |
| R48343 | T36887 | T11592 | arg1Of | antibody,47D11 |
| R48482 | T96346 | T9479 | arg1Of | and,"," |
| R48595 | T44833 | T11300 | arg1Of | displayed,"," |
| R48681 | T61991 | T18474 | arg1Of | study,[ |
| R48731 | T59356 | T69055 | arg2Of | signs,have |
| R4907 | T85855 | T10850 | arg1Of | use,is |
| R49211 | T1922 | T22947 | arg2Of | is,as |
| R49421 | T1824 | T60055 | arg1Of | absorbed,in |
| R5031 | T20998 | T79456 | arg1Of | 6.1,Targeting |
| R5059 | T24633 | T10954 | arg1Of | It,important |
| R50655 | T88887 | T30470 | arg1Of | ",",and |
| R50898 | T98095 | T52540 | arg1Of | chains,human |
| R50965 | T66286 | T14012 | arg1Of | treatment,tocilizumab |
| R51485 | T27554 | T57621 | arg2Of | subunit,of |
| R51826 | T82065 | T3419 | arg1Of | –,block |
| R51850 | T94537 | T18203 | arg2Of | and,showed |
| R51991 | T5967 | T65069 | arg2Of | light,and |
| R52641 | T29466 | T64967 | arg1Of | antibody,human |
| R52958 | T40665 | T11788 | arg2Of | antibodies,detect |
| R52999 | T66055 | T80340 | arg1Of | condition,was |
| R53041 | T58078 | T92236 | arg1Of | as,Currently |
| R53068 | T96963 | T31917 | arg2Of | level,had |
| R53187 | T96963 | T24848 | arg1Of | level,mean |
| R53417 | T89003 | T20163 | arg1Of | subunit,the |
| R5373 | T90933 | T6930 | arg2Of | more,of |
| R53734 | T24534 | T96881 | arg2Of | two,or |
| R53752 | T80909 | T71888 | arg1Of | and,induced |
| R53767 | T86465 | T1893 | arg1Of | binding,to |
| R53814 | T29466 | T20950 | arg1Of | antibody,a |
| R54102 | T93532 | T80345 | arg1Of | virus,the |
| R54223 | T78367 | T10850 | arg2Of | recommended,is |
| R54251 | T68140 | T69338 | arg1Of | affinities,similar |
| R54339 | T25625 | T44775 | arg1Of | cells,VeroE6 |
| R54748 | T98095 | T72563 | arg1Of | chains,heavy |
| R5494 | T56884 | T91479 | arg1Of | binding,the |
| R55425 | T57345 | T78516 | arg1Of | antibody,One |
| R55511 | T12942 | T48321 | arg1Of | binding,to |
| R5554 | T60803 | T94537 | arg1Of | improvement,and |
| R55576 | T33177 | T18503 | arg2Of | 26,[ |
| R55812 | T3419 | T69422 | arg1Of | block,not |
| R56159 | T50204 | T20973 | arg1Of | occurred,with |
| R56313 | T62141 | T93322 | arg1Of | arthritis,juvenile |
| R56743 | T98192 | T20616 | arg2Of | plus,of |
| R56902 | T69919 | T49873 | arg2Of | effective,be |
| R57258 | T90933 | T81944 | arg1Of | more,than |
| R5731 | T70238 | T24534 | arg1Of | doses,two |
| R57443 | T9970 | T55531 | arg1Of | domain,binding |
| R57671 | T62141 | T49595 | arg1Of | arthritis,idiopathic |
| R57766 | T18211 | T39196 | arg1Of | SARS-S,and |
| R57799 | T45371 | T75403 | arg1Of | It,may |
| R57903 | T63070 | T34390 | arg1Of | levels,proportion |
| R57926 | T49873 | T22947 | arg1Of | be,as |
| R58214 | T53882 | T32471 | arg2Of | FDA,by |
| R58250 | T17328 | T16199 | modOf | Hypothesis,can |
| R58716 | T37470 | T22676 | arg2Of | SARS2-S,and |
| R58839 | T74401 | T75556 | arg1Of | mAb,against |
| R5884 | T29466 | T27300 | arg1Of | antibody,( |
| R58851 | T37245 | T52983 | arg1Of | activity,a |
| R59110 | T29313 | T97739 | arg2Of | 28,[ |
| R59163 | T1902 | T34125 | arg2Of | and,with |
| R59437 | T54700 | T30269 | arg1Of | arthritis,rheumatoid |
| R59576 | T9137 | T45333 | arg2Of | severe,and |
| R60119 | T36466 | T17580 | arg1Of | patients,who |
| R60499 | T22184 | T1922 | arg1Of | it,is |
| R60586 | T65701 | T99390 | arg2Of | counts,"," |
| R60594 | T83081 | T39196 | arg2Of | SARS-2-S,and |
| R60939 | T90119 | T59846 | arg1Of | inflammatory,and |
| R61251 | T2749 | T61983 | arg2Of | COVID-19,with |
| R61440 | T58005 | T98192 | arg2Of | therapy,plus |
| R61441 | T58078 | T32112 | arg1Of | as,"," |
| R6154 | T59356 | T65527 | arg1Of | signs,of |
| R61551 | T14228 | T81402 | arg1Of | symptoms,clinical |
| R62361 | T36887 | T2922 | arg1Of | antibody,the |
| R62516 | T26978 | T79137 | arg1Of | virus,[ |
| R62752 | T34900 | T84268 | arg1Of | and,for |
| R63011 | T17100 | T66535 | arg2Of | mice,from |
| R63116 | T78221 | T14738 | arg1Of | and,the |
| R63345 | T18121 | T28665 | arg2Of | and,is |
| R6420 | T1902 | T37015 | arg1Of | and,for |
| R64318 | T65699 | T98539 | arg2Of | deaths,nor |
| R6462 | T44785 | T43571 | arg2Of | atlizumab,as |
| R6463 | T49873 | T60557 | arg1Of | be,in |
| R64820 | T96891 | T41163 | arg1Of | Hypothesis,: |
| R64854 | T82065 | T4372 | arg1Of | –,S1B |
| R65301 | T58761 | T96810 | arg1Of | is,"," |
| R65601 | T70238 | T20616 | arg1Of | doses,of |
| R65646 | T72012 | T36716 | arg1Of | supernatants,were |
| R65763 | T25454 | T28665 | arg1Of | It,is |
| R65895 | T24185 | T29074 | arg1Of | antibody,anti-human |
| R66809 | T14228 | T44490 | arg2Of | symptoms,in |
| R66835 | T74827 | T56144 | arg1Of | used,"," |
| R66912 | T72581 | T30814 | arg2Of | formation,decreased |
| R66943 | T85855 | T54987 | arg1Of | use,the |
| R66954 | T24269 | T26765 | arg1Of | There,are |
| R67132 | T70238 | T98598 | arg1Of | doses,one |
| R67139 | T74827 | T36716 | arg2Of | used,were |
| R67161 | T22676 | T19104 | arg2Of | and,against |
| R6725 | T37245 | T30646 | arg1Of | activity,cross-neutralizing |
| R67300 | T86465 | T37015 | arg2Of | binding,for |
| R67692 | T75964 | T34900 | arg2Of | normalization,and |
| R6780 | T7888 | T95236 | arg2Of | compete,could |
| R67837 | T72012 | T74827 | arg2Of | supernatants,used |
| R67960 | T51640 | T22676 | arg1Of | SARS-S,and |
| R6804 | T36310 | T48409 | arg1Of | infection,SARS-CoV2 |
| R68061 | T1922 | T38972 | arg1Of | is,vitro |
| R68271 | T30323 | T36542 | arg1Of | ",",and |
| R68664 | T49873 | T85248 | arg2Of | be,might |
| R6870 | T11815 | T63608 | arg1Of | Rational,6.1.2 |
| R6871 | T96386 | T80967 | arg1Of | that,for |
| R68866 | T41843 | T53652 | arg1Of | neutralizing,By |
| R68969 | T95631 | T77580 | arg2Of | interacting,for |
| R68991 | T95558 | T79137 | arg2Of | 26,[ |
| R69341 | T11788 | T74827 | arg3Of | detect,used |
| R69456 | T24628 | T76208 | arg2Of | patients,in |
| R69683 | T47874 | T61532 | arg1Of | affinity,higher |
| R69719 | T79617 | T2754 | arg1Of | cytokines,pro-inflammatory |
| R6992 | T36887 | T11559 | arg2Of | antibody,of |
| R6996 | T98095 | T35586 | arg1Of | chains,immunoglobulin |
| R70086 | T34654 | T35671 | arg2Of | and,neutralize |
| R70730 | T38972 | T72123 | arg1Of | vitro,in |
| R71645 | T15312 | T18121 | arg1Of | safe,and |
| R71674 | T85855 | T75237 | arg1Of | use,can |
| R72696 | T83617 | T75556 | arg2Of | IL6,against |
| R72772 | T59356 | T71996 | arg1Of | signs,warning |
| R72983 | T78367 | T54453 | arg1Of | recommended,"," |
| R73215 | T57345 | T43362 | arg1Of | antibody,could |
| R73472 | T93924 | T49873 | arg1Of | H2L2,be |
| R73905 | T27554 | T77993 | arg1Of | subunit,the |
| R73916 | T25577 | T56819 | arg1Of | protein,S |
| R73965 | T68140 | T88888 | arg1Of | affinities,of |
| R74139 | T57345 | T83927 | arg1Of | antibody,H2L2 |
| R74424 | T98598 | T96881 | arg1Of | one,or |
| R74668 | T83470 | T34654 | arg2Of | SARS-2-S,and |
| R74716 | T48435 | T19104 | arg1Of | protect,against |
| R74784 | T68840 | T67953 | arg2Of | attenuate,can |
| R74916 | T17100 | T66245 | arg1Of | mice,transgenic |
| R74963 | T79215 | T85453 | arg1Of | patients,received |
| R75181 | T30814 | T11300 | arg2Of | decreased,"," |
| R75326 | T85453 | T21073 | arg1Of | received,In |
| R75716 | T54390 | T7377 | arg1Of | 6.2,Targeting |
| R75826 | T96963 | T15301 | arg1Of | level,a |
| R76104 | T41529 | T48683 | arg2Of | patients,of |
| R76550 | T58130 | T31522 | arg1Of | critical,and |
| R7667 | T25878 | T32221 | arg1Of | mAb,A |
| R76769 | T92225 | T58130 | arg1Of | COVID-19,critical |
| R76811 | T26283 | T43571 | arg1Of | known,as |
| R76879 | T93532 | T76093 | arg2Of | virus,of |
| R77190 | T66576 | T19164 | arg1Of | years,and |
| R77316 | T54016 | T97739 | arg3Of | ],[ |
| R77360 | T38357 | T89869 | arg1Of | and,both |
| R7737 | T56920 | T32531 | arg1Of | regions,immunoglobulin |
| R77514 | T47874 | T96386 | arg1Of | affinity,that |
| R77534 | T24185 | T17221 | arg2Of | antibody,approved |
| R77806 | T40665 | T56747 | arg1Of | antibodies,that |
| R78022 | T66055 | T55941 | arg1Of | condition,critical |
| R78190 | T47874 | T77580 | arg1Of | affinity,for |
| R78219 | T80909 | T44111 | arg2Of | and,by |
| R78333 | T32842 | T38357 | arg1Of | adults,and |
| R78533 | T42834 | T11331 | arg2Of | patients,in |
| R78642 | T84664 | T9387 | arg1Of | treatment,tocilizumab |
| R78842 | T98095 | T78221 | arg1Of | chains,and |
| R79151 | T56884 | T11559 | arg1Of | binding,of |
| R79228 | T79215 | T77821 | arg1Of | patients,21 |
| R79302 | T57345 | T48435 | arg1Of | antibody,protect |
| R79461 | T72012 | T55915 | arg1Of | supernatants,hybridoma |
| R79527 | T74401 | T35174 | arg1Of | mAb,A |
| R79687 | T92225 | T15777 | arg2Of | COVID-19,with |
| R79824 | T2467 | T18121 | arg2Of | effective,and |
| R79844 | T68837 | T81658 | arg1Of | ",","," |
| R79916 | T84664 | T64021 | arg2Of | treatment,before |
| R79941 | T66286 | T20973 | arg2Of | treatment,with |
| R80450 | T8341 | T18474 | arg2Of | 27,[ |
| R80686 | T66576 | T46590 | arg1Of | years,of |
| R80894 | T58622 | T53652 | arg2Of | contrast,By |
| R81151 | T68894 | T32288 | arg2Of | that,than |
| R81194 | T55941 | T44653 | arg2Of | critical,or |
| R81304 | T38357 | T39207 | arg2Of | and,for |
| R81579 | T25577 | T24060 | arg1Of | protein,the |
| R8185 | T96625 | T18203 | arg1Of | Patients,showed |
| R81985 | T1824 | T31791 | arg1Of | absorbed,Also |
| R82088 | T18877 | T18503 | arg1Of | receptor,[ |
| R8244 | T63070 | T84268 | arg2Of | levels,for |
| R82868 | T86439 | T26283 | arg2Of | Tocilizumab,known |
| R82985 | T80638 | T76208 | arg1Of | treat,in |
| R82994 | T61991 | T65150 | arg1Of | study,the |
| R83125 | T86439 | T21494 | arg1Of | Tocilizumab,"," |
| R83390 | T51141 | T88469 | arg1Of | score,H |
| R84017 | T58127 | T80909 | arg2Of | SARS2-S,and |
| R8404 | T37245 | T94688 | arg1Of | activity,such |
| R84051 | T68140 | T48175 | arg1Of | affinities,its |
| R84073 | T96891 | T67953 | arg1Of | Hypothesis,can |
| R84082 | T68140 | T71055 | arg1Of | affinities,"," |
| R84172 | T75582 | T89299 | arg2Of | COVID-19,whose |
| R84230 | T81589 | T7888 | arg2Of | antibodies,compete |
| R84332 | T3706 | T87509 | arg1Of | Rationale,: |
| R84932 | T53845 | T7496 | arg2Of | measured,be |
| R85163 | T73637 | T99819 | arg2Of | S1B,i.e. |
| R85183 | T98539 | T15021 | arg1Of | nor,adverse |
| R85187 | T39196 | T24571 | arg1Of | and,both |
| R85301 | T93924 | T85248 | arg1Of | H2L2,might |
| R85448 | T38357 | T66576 | arg1Of | and,years |
| R85482 | T78367 | T58078 | arg1Of | recommended,as |
| R85602 | T49873 | T92338 | arg1Of | be,not |
| R8563 | T68140 | T91829 | arg2Of | affinities,in |
| R85705 | T67288 | T38598 | arg1Of | %,90 |
| R85824 | T57345 | T34464 | arg1Of | antibody,chimeric |
| R86004 | T72411 | T46139 | arg1Of | Tocilizumab,can |
| R86212 | T46803 | T90119 | arg1Of | diseases,inflammatory |
| R86711 | T39196 | T80967 | arg2Of | and,for |
| R86934 | T18121 | T39207 | arg1Of | and,for |
| R8726 | T98139 | T85324 | arg1Of | repertoires,that |
| R87268 | T56920 | T19776 | arg1Of | regions,origin |
| R87485 | T46803 | T31666 | arg1Of | diseases,autoimmune |
| R87538 | T85855 | T53845 | arg2Of | use,measured |
| R87567 | T32517 | T97000 | arg2Of | SARS-2-S.,of |
| R87665 | T25454 | T2467 | arg1Of | It,effective |
| R87983 | T35671 | T54239 | arg2Of | neutralize,can |
| R88261 | T96963 | T84688 | arg1Of | level,IL6 |
| R88299 | T63070 | T30755 | arg1Of | levels,CRP |
| R88560 | T77445 | T34654 | arg1Of | SARS-S,and |
| R89076 | T88455 | T77671 | arg1Of | IL6,"," |
| R8917 | T40665 | T35671 | arg1Of | antibodies,neutralize |
| R89241 | T27842 | T23786 | arg1Of | COVID-19,moderate |
| R89642 | T35671 | T76245 | arg1Of | neutralize,[ |
| R89881 | T85855 | T69355 | arg1Of | use,of |
| R89899 | T68912 | T98192 | arg1Of | Tocilizumab,plus |
| R8993 | T65701 | T23484 | arg1Of | counts,platelet |
| R89938 | T91104 | T97128 | arg2Of | SARS-2-S,and |
| R89954 | T67288 | T60055 | arg2Of | %,in |
| R9002 | T3706 | T41884 | arg1Of | Rationale,6.2.2 |
| R90450 | T10130 | T31388 | arg1Of | opacity,was |
| R90482 | T88114 | T14365 | arg1Of | injury,lung |
| R90538 | T46803 | T80969 | arg1Of | diseases,severe |
| R90654 | T66055 | T3490 | arg1Of | condition,severe |
| R90774 | T35808 | T34900 | arg1Of | saturation,and |
| R90910 | T1824 | T31152 | arg1Of | absorbed,"," |
| R90990 | T98139 | T24138 | arg1Of | repertoires,antibody |
| R91010 | T18877 | T48321 | arg2Of | receptor,to |
| R91021 | T93924 | T42126 | arg1Of | H2L2,47D11 |
| R91084 | T67288 | T48683 | arg1Of | %,of |
| R91166 | T57345 | T13041 | arg1Of | antibody,47D11 |
| R91228 | T96625 | T31917 | arg1Of | Patients,had |
| R91476 | T82716 | T5151 | arg1Of | Development,of |
| R91506 | T78221 | T55347 | arg2Of | and,express |
| R91756 | T86439 | T58761 | arg1Of | Tocilizumab,is |
| R91773 | T25878 | T8625 | arg1Of | mAb,against |
| R92122 | T81575 | T72053 | arg1Of | markers,inflammatory |
| R92175 | T15404 | T46590 | arg2Of | age,of |
| R92198 | T72411 | T80638 | arg1Of | Tocilizumab,treat |
| R92213 | T9970 | T32030 | arg1Of | domain,the |
| R92270 | T96891 | T42975 | arg1Of | Hypothesis,6.2.1 |
| R92294 | T56920 | T28318 | arg1Of | regions,rat |
| R92393 | T35808 | T83697 | arg1Of | saturation,peripheral |
| R92430 | T24633 | T45480 | arg1Of | It,is |
| R92489 | T40115 | T69355 | arg2Of | Tocilizumab,of |
| R92565 | T99390 | T30323 | arg1Of | ",","," |
| R92610 | T24185 | T43255 | arg1Of | antibody,as |
| R92720 | T36466 | T61983 | arg1Of | patients,with |
| R92728 | T38362 | T39715 | arg1Of | interacting,with |
| R93366 | T72012 | T47163 | arg1Of | supernatants,containing |
| R93465 | T79617 | T7377 | arg2Of | cytokines,Targeting |
| R93944 | T78367 | T33042 | arg1Of | recommended,for |
| R94262 | T68003 | T26765 | arg2Of | trials,are |
| R94310 | T53845 | T58078 | arg2Of | measured,as |
| R9435 | T36310 | T28417 | arg2Of | infection,inhibit |
| R94369 | T75581 | T81944 | arg2Of | 100 pg/ml,than |
| R94533 | T72563 | T65069 | arg1Of | heavy,and |
| R94556 | T92661 | T68840 | arg2Of | inflammation,attenuate |
| R94676 | T98139 | T66535 | arg1Of | repertoires,from |
| R95020 | T24277 | T1902 | arg2Of | S2,and |
| R95470 | T83078 | T11331 | arg1Of | treatment,in |
| R95568 | T18333 | T86725 | arg1Of | cells,lung |
| R96088 | T96963 | T6930 | arg1Of | level,of |
| R96321 | T48435 | T96346 | arg2Of | protect,and |
| R96452 | T7869 | T80909 | arg1Of | SARS-S,and |
| R96775 | T89813 | T95236 | arg1Of | SARS-S,could |
| R96842 | T53845 | T75237 | arg2Of | measured,can |
| R96846 | T15987 | T81658 | arg2Of | arteritis,"," |
| R96954 | T36466 | T33042 | arg2Of | patients,for |
| R97104 | T27842 | T9137 | arg1Of | COVID-19,severe |
| R97129 | T82065 | T31100 | arg1Of | –,domain |
| R97168 | T34390 | T96610 | arg1Of | proportion,and |
| R97353 | T58005 | T20706 | arg1Of | therapy,standard |
| R9737 | T49120 | T55070 | arg1Of | S1B,and |
| R97819 | T17221 | T13017 | arg1Of | approved,"," |
| R98023 | T18333 | T60557 | arg2Of | cells,in |
| R98220 | T85453 | T29393 | arg1Of | received,"," |
| R98342 | T56920 | T16968 | arg1Of | regions,constant |
| R98822 | T92661 | T2426 | arg1Of | inflammation,hyper |
| R9904 | T10130 | T51431 | arg1Of | opacity,lesion |
| R99048 | T81589 | T41843 | arg1Of | antibodies,neutralizing |
| R99138 | T10130 | T79595 | arg1Of | opacity,lung |
| R99609 | T12942 | T3419 | arg2Of | binding,block |
| R99891 | T6430 | T18474 | arg3Of | ],[ |
| R99987 | T11815 | T73902 | arg1Of | Rational,: |